Sign Up Today and Learn More About MapLight Therapeutics Stock
Invest in or calculate the value of your shares in MapLight Therapeutics or other pre-IPO companies through EquityZen's platform.
MapLight Therapeutics Stock (MAPT)
MapLight Therapeutics is a biopharma company that offers a platform designed to discover and develop therapeutics for brain disorders.
About MapLight Therapeutics Stock
Founded
2018
Headquarters
Palo Alto, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
MapLight Therapeutics Press Mentions
Stay in the know about the latest news on MapLight Therapeutics
Eil Therapeutics patent details Bcl-2 inhibitors
bioworld • Apr 10, 2025
Autism Spectrum Disorder Markets Expected to Exhibit a CAGR Of 5.84% During 2025-2035, impelled by Innovative Treatments
biospace • Feb 13, 2025
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
biospace • Jan 06, 2025
Preclinical efficacy of M1/M4 receptor agonist in schizophrenia, cognitive impairment models
bioworld • Dec 12, 2024
MAPLIGHT THERAPEUTICS ANNOUNCES RESULTS FROM PHASE 1 TRIAL OF NOVEL M1/M4 MUSCARINIC AGONIST IN DEVELOPMENT FOR TREATMENT OF SCHIZOPHRENIA AND ALZHEIMER'S DISEASE PSYCHOSIS
prnewswire • Dec 03, 2024
MapLight Therapeutics Management
Leadership team at MapLight Therapeutics
Co-Founder
Karoly Nikolich
Co-Founder & CEO
Chris Kroeger
Join now and verify your accreditation status to gain access to:
- MapLight Therapeutics Current Valuation
- MapLight Therapeutics Stock Price
- MapLight Therapeutics Management
- Available deals in MapLight Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- MapLight Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- MapLight Therapeutics Revenue and Financials
- MapLight Therapeutics Highlights
- MapLight Therapeutics Business Model
- MapLight Therapeutics Risk Factors
- MapLight Therapeutics Research Report from SACRA Research
Trading MapLight Therapeutics Stock
How to invest in MapLight Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like MapLight Therapeutics through EquityZen funds. These investments are made available by existing MapLight Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell MapLight Therapeutics stock?
Shareholders can sell their MapLight Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
